http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-20001912-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94ff2d78578d95d1e8d3a2233c76188d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
| filingDate | 1998-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b78399a0ff2bbcb5e5fa7c4cbf9f997 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_507cd61676f585e1311c6733303c7e16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd00b93ae0d0d8d1231baa288b73ab47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bc551d6c2e0f4e8b3259a23a1c919e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ab60d66d8136bbbbd9a1e5dd2a7426e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67dc237fd7df6147cd42e69653427fac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48cfe96df6a943b22c2465d21166dadb |
| publicationDate | 2000-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-20001912-A3 |
| titleOfInvention | 5- (2-Imidazolinylamino) -benzimidazole derivatives, their preparation and their use as alpha adrenoceptor agonists with improved metabolic stability |
| abstract | The present invention relates to compounds having the structure according to the inventionnof formula (I) wherein: (a) R1 is alkyl; (b) R 2 is selected fromna group consisting of: hydrogen, alkyl, methoxy, cyano, andnhalogen; (c) R3 is selected from the group consisting of:nhydrogen, methyl, hydroxy, cyano and halogen; (d) R4 isnselected from the group consisting of: hydrogen, methyl, ethylnand isopropyl; (e) R5 is selected from the group consisting of:nhydrogen, methyl, amino, methoxy, hydroxy, cyano and halogen;n(f) provided that at least one of R 2, R 3, R 4 or R 5 isnother than hydrogen or fluorine; (g) provided that when R1 isnboth methyl and R 2 and R 5 are hydrogen, R 3 is other than methylnor halogen; (h) provided that R 3 is cyano, R 1 isnmethyl; and any tautomer of the above structure or itsna pharmaceutically acceptable salt, or a biohydrolyzable salt thereofnan ester, amide or imide. The compounds of the invention arenperipherally acting selective alpha-2 adrenergic compounds that reduce central nervous system action and resistnmetabolic conversion to undesirable compounds. |
| priorityDate | 1998-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 511.